Viking Therapeutics (VKTX) Share-based Compensation (2014 - 2026)

Viking Therapeutics has reported Share-based Compensation for 13 years, with the latest figure at $11.1 million in Q2 2026.

• Quarterly Share-based Compensation fell 17.82% year-over-year to $11.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $43.6 million (up 28.71% YoY) and the FY2025 annual result came in at $40.8 million, down 3.05% from the prior year.
• Share-based Compensation advanced to $11.1 million in Q2 2026 per VKTX's latest filing, from $10.3 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $42.1 million in Q1 2024 and troughed at $1.9 million in Q3 2022.
• A 5-year average of $9.5 million and a median of $7.1 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation soared 961.55% in 2024, then sank 73.05% in 2025.
• Over 5 years, Share-based Compensation stood at $2.2 million in 2022, then soared by 89.24% to $4.1 million in 2023, then surged by 120.15% to $9.0 million in 2024, then dropped by 4.4% to $8.6 million in 2025, then grew by 29.65% to $11.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $11.1 million, $10.3 million, and $8.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.